Viatris (VTRS) Backs Phage Therapy for Eye Infections Might Change The Case For Investing

• Locus Biosciences announced a research collaboration with Viatris Inc. to develop engineered bacteriophage therapies targeting serious ophthalmic bacterial infections, aiming to address the growing medical challenge of antibiotic resistance worldwide.
• This partnership leverages Locus's proprietary AI and synthetic biology platform, signaling Viatris's commitment to pioneering next-generation antibacterial solutions in areas of high unmet clinical need.
• We'll examine how Viatris's investment in phage therapy innovation could reshape its long-term growth outlook and product pipeline strategy.

Find companies with promising cash flow potential yet trading below their fair value.

Viatris Investment Narrative Recap

Viatris shareholders need to believe in the company’s ability to transition from a reliance on mature generics toward a more innovative, diversified portfolio, especially as it faces ongoing price pressure and regulatory scrutiny in major markets. The new collaboration with Locus Biosciences highlights an intent to drive long-term growth through next-generation therapies, but its near-term impact appears limited, with the upcoming earnings release and persistent pricing headwinds remaining the most important short-term catalysts and risks.

Among recent announcements, the amended and restated company bylaws signal continued management action on corporate governance. While this is a positive for oversight, it does not materially alter the current risk profile or address potential delays in translating new R&D partnerships into tangible earnings results.

In contrast, investors should be aware that heavy reliance on off-patent products still exposes Viatris to revenue risks if...

Read the full narrative on Viatris (it's free!)

Viatris' narrative projects $14.5 billion revenue and $419.7 million earnings by 2028. This scenario assumes a -0.9% annual revenue decline and an earnings increase of about $3.92 billion from current earnings of -$3.5 billion.

Uncover how Viatris' forecasts yield a $11.88 fair value, a 14% upside to its current price.

Exploring Other Perspectives

Seven fair value estimates from the Simply Wall St Community range from US$10.47 up to US$44.88 per share. Against this backdrop, the company’s slow forecast revenue growth could limit upward movement, so consider several viewpoints on future performance.

Explore 7 other fair value estimates on Viatris - why the stock might be worth just $10.47!

Build Your Own Viatris Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Viatris research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Viatris research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Viatris' overall financial health at a glance.

Curious About Other Options?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• AI is about to change healthcare. These 34 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Uncover the next big thing with financially sound penny stocks that balance risk and reward.
• Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com